FDA Approves Pimicotinib for Tenosynovial Giant Cell Tumor as WHO Mobilizes Over 240 Institutions for Science Trust
The U.S. FDA approved the kinase inhibitor pimicotinib (Pimjetmi) under Project Orbis after the MANEUVER trial demonstrated a 56% overall response rate, while the World Health Organization launched its 'Together for Science and Health' movement and 2026–2028 ATACH climate-health priorities.
By 全球伯乐 News
Biomedicine & Public Health Desk
On this page
On November 10, 2026, the U.S. Food and Drug Administration (FDA) approved pimicotinib (Pimjetmi, EMD Serono, Inc.), an oral kinase inhibitor, for adults with symptomatic tenosynovial giant cell tumor (TGCT) for whom surgical resection could cause worsening functional limitation or severe morbidity1. On the same day, the World Health Organization (WHO) launched the 'Together for Science and Health' movement in Geneva and at the Paris Peace Forum, uniting more than 240 organizations to safeguard scientific evidence amid rapid artificial intelligence adoption2, while convening health ministers at COP31 in Antalya to roll out the 2026–2028 priorities of the Alliance for Transformative Action on Climate and Health (ATACH)3.

AI-generated illustration: Editorial still-life concept representing targeted oncology drug review and global evidence-based public health cooperation, not a clinical photograph.
MANEUVER Trial 56% Overall Response Rate and Six-Nation Project Orbis Review
According to the FDA Oncology Center of Excellence approval announcement, pimicotinib's efficacy was established in MANEUVER (NCT05804045), a randomized (2:1), double-blind, placebo-controlled international trial stratified by geographic region (China versus non-China) in adults with measurable symptomatic TGCT lesions of at least 2 cm receiving 50 mg orally once daily1. Assessed by blinded independent central review (BICR) per RECIST v1.1 at Week 25, the overall response rate (ORR) reached 56% (95% CI: 42, 68) in the pimicotinib arm compared with 3.2% (95% CI: 0.1, 17) in the placebo arm; median duration of response (DOR) was not reached, with 91% of responders (32 patients) maintaining responses for at least 6 months and 77% (27 patients) for at least 12 months1.
Patients treated with pimicotinib also achieved statistically significant improvements at Week 25 across prespecified functional and patient-reported endpoints, including active joint range of motion by goniometry, Brief Pain Inventory (BPI) Worst Pain Numeric Rating Scale scores, and PROMIS Physical Function T-scores, with labeling warnings for hepatotoxicity, embryo-fetal toxicity, and non-renal serum creatinine elevation1. Conducted under Project Orbis with Fast Track and Breakthrough Therapy designations, the review brought together the FDA, Australia's TGA, Health Canada, Israel's Ministry of Health, Switzerland's Swissmedic, and the UK's MHRA (with the European Medicines Agency as official observer), underscoring how international regulatory convergence is accelerating patient access to rare tumor therapies1.
WHO Mobilizes 240+ Partners on AI-Era Science Trust and Launches ATACH 2026–2028 Mechanisms
Parallel to regulatory advances in clinical oncology, global health authorities moved to shore up public confidence in scientific evidence. Led by WHO Director-General Dr. Tedros Adhanom Ghebreyesus and French President Emmanuel Macron alongside the Paris Peace Forum on World Science Day for Peace and Development, the 'Together for Science and Health' coalition spans more than 240 institutions and 12 regional launch events focused on connecting science with society, embedding evidence in health policymaking, and upgrading science communication2. WHO Chief Scientist Dr. Sylvie Briand emphasized that as artificial intelligence rapidly alters how citizens access and interpret health guidance, institutions must build collaborative networks that counter polarization and translate trusted research into public health outcomes2.
At the fourth ATACH Day held at the COP31 Health Pavilion in Antalya, Turkish Health Minister Prof. Dr. Kemal Memişoğlu and Australian CDC Director General Prof. Zoe Wainer joined health ministers from Brazil, the Bahamas, North Macedonia, and Tuvalu to operationalize the Antalya Initiative for Health Resilience (AIR), coordinated technically through the WHO-hosted ATACH Secretariat3. ATACH Secretariat Lead Elena Villalobos Prats unveiled the Alliance's 2026–2028 workplan alongside two new capacity-building instruments—ATACH thematic Communities of Practice and an Executive Fellowship—designed to help Small Island Developing States (SIDS) and Least Developed Countries (LDCs) finance and implement climate-resilient health systems123.
Source notes
-
2026-11-10 · FDA approves pimicotinib for symptomatic tenosynovial giant cell tumor · U.S. Food and Drug Administration (FDA). ↩ ↩2 ↩3 ↩4 ↩5 ↩6
-
2026-11-10 · WHO launches “Together for Science and Health” movement to strengthen trust worldwide · World Health Organization (WHO). ↩ ↩2 ↩3 ↩4
-
2026-11-10 · From commitments to implementation: ATACH Day at COP31 delivers practical solutions for climate and health · World Health Organization (WHO). ↩ ↩2 ↩3


